Treatment of human intestinal cryptosporidiosis: A review of published clinical trials
- PMID: 34562754
- PMCID: PMC8473663
- DOI: 10.1016/j.ijpddr.2021.09.001
Treatment of human intestinal cryptosporidiosis: A review of published clinical trials
Abstract
The global burden of diarrhea caused by Cryptosporidium parasite is underestimated. In immunocompromised hosts, chronic and severe presentation of intestinal cryptosporidiosis can result in long-term morbidity and high illness costs. The evidence of effective treatments for cryptosporidiosis has been lacking. We reviewed the published clinical trials to bring forward the feasible therapeutic options of human cryptosporidiosis in various populations and settings according to clinical improvement and parasite clearance rates. A total of 42 studies consisting of the use of nitazoxanide, paromomycin, macrolides, somatostatin analogues, letrazuril, albendazole, rifaximin, miltefosine, clofazimine, and colostrum were included in the review. The trials were mostly conducted in small number of individuals infected with human immunodeficiency virus (HIV), and there is inadequate data of controlled trials to suggest the use of these treatment modalities. Nitazoxanide was reported to be highly efficacious only in immunocompetent hosts and was found to be superior to paromomycin in the same group of patients. Macrolides showed no effective results in both clinical and parasitological improvement. Human bovine colostrum should possibly be administered as one of complementary therapeutic modalities along with other antimicrobials to reach optimal parasite eradication. Other trials of therapeutic modalities were terminated due to futility. Currently, available data is intended to aid the development of strategies for improving access to treatments in different clinical settings, as well as to help guide further studies on treatments of human intestinal cryptosporidiosis.
Keywords: Clearance; Clinical trial; Cryptosporidiosis; Cryptosporidium; Drug; Treatment.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
References
-
- Abaza B.E., Hamza R.S., Farag T.I., Abdel-Hamid M.A., Moustafa R.A. Assessing the efficacy of nitazoxanide in treatment of cryptosporidiosis using PCR examination. J. Egypt. Soc. Parasitol. 2016;46:683–692. - PubMed
-
- Ahmadpour E., Safarpour H., Xiao L., Zarean M., Hatam-Nahavandi K., Barac A., Picot S., Rahimi M.T., Rubino S., Mahami-Oskouei M., Spotin A., Nami S., Baghi H.B. Cryptosporidiosis in HIV-positive patients and related risk factors: a systematic review and meta-analysis. Parasite. 2020;27 27-27. - PMC - PubMed
-
- Ali S., Kumar S. Treatment outcomes with nitazoxanide in immunocompetent adults naive patients with cryptosporidiosis; do we need combination therapy with paromomycin or azithromycin? Trop Med Surg. 2015;3
-
- Amadi B., Mwiya M., Musuku J., Watuka A., Sianongo S., Ayoub A., Kelly P. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet. 2002;360:1375–1380. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
